Putting Your Best Pharmacoeconomic Evidence Forward
As the HTA requirements for local reimbursement submissions continue to evolve, it is crucial that your market access team has an in-depth understanding of how to successfully develop a local submission dossier. The objective of this meeting is to participate to gain insight into key methodological requirements for pharmaeconomic studies submitted to Zorginstituut Nederland for reimbursement appraisal.
A general overview of the ZiN requirements for a successful submission of pharmacoeconomic evidence is presented.
European collaboration on relative effectiveness assessments has received a lot of attention recently. This collaboration may impact evidence requirements on a local/national level substantially. Moreover, other relevant developments in early access of new pharmaceuticals as part of adaptive pathways will also affect these HTA evidence requirements. In this presentation both developments are linked and discussed in relation to the needs and requirements of the local/national authorities.
An overview of the appropriate methods for gathering evidence will be presented, followed by methods for evidence synthesis such as (standard) meta-analysis, indirect treatment comparison (ITC) and network meta-analysis (NMA). Terminology, assumptions, validity, methods (frequentist vs. Bayesian) and interpretation of results are discussed.
During this session, guidance is provided on the interpretation of indirect treatment comparisons and network meta-analysis to assist professionals in using its findings for incorporation into health economic models used for submissions. Furthermore, advice is provided on how to critically review evidence synthesis with a view on informing local requirements.
The requirements for economic modeling studies as set-forth by ZiN is discussed alongside common pitfalls to be avoided when submitting health economic models.
During this session, key challenges with adapting core models for the Dutch setting are discussed. The experiences from a market access manager perspective and Mapi is also presented along with insights into how to overcome the risks to a successful model adaptation.
This Patient-Centered Research Workshop was presented on April 23 2015, in Maarsen. Mapi and industry experts including Dr. Wim Goettsch (EUNetHTA/GetReal), Peter Fassler (AbbVie B.V.), and Dr. Maiwenn Al (Eramus University Rotterdam) shared their experience and expertise with attendees from across the industry. We would love to present this workshop for your team or at your tradeshow. To find out more, contact Mapi at email@example.com
Download Summary PDF
To download a PDF summary of this workshop from a recent event, please complete the following form.
At our Patient-Centered Research workshops, Mapi experts share their knowledge, insights, and experience on topics that are vital to a project’s success. As one of the leading voices in patient-centered research, Mapi is happy to share our expertise with the industry.
At Mapi, we know that research centered on people is crucial to improving world health. Our unrivaled four decades of operational expertise in generating, synthesizing, and analyzing Real World Evidence and Health Economics Outcomes Research has established Mapi Group as the industry leader and recognized innovator of Outcomes Research methodologies and sciences.
Our research solutions bridge the distance between life science companies and patients, enabling market access and navigating the complex global regulatory environment.
Our commitment runs deep. Mapi Group is the only Health Research Company with a direct-funded non-profit organization dedicated to improving Patient Outcomes and Quality of Life. The Mapi Research Trust supports thousands of independent and academic research programs every year in over 130 countries, offering free and subsidized access to Clinical Outcomes Assessments (COA), their derivatives, and translations.